363 related articles for article (PubMed ID: 12420443)
1. To market, to market. The nuts and bolts of prescription drug approval.
Peterson AM
Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443
[No Abstract] [Full Text] [Related]
2. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
[No Abstract] [Full Text] [Related]
3. Regulating the fate of pharmaceutical drugs: a new prescription for the environment.
Nidel CT
Food Drug Law J; 2003; 58(1):81-101. PubMed ID: 12739585
[No Abstract] [Full Text] [Related]
4. US court rules to allow experimental drugs for dying patients.
Waltz E
Nat Med; 2006 Jun; 12(6):596. PubMed ID: 16760988
[No Abstract] [Full Text] [Related]
5. Ethical implications of pediatric drug research policy initiatives.
Twomey JG
IRB; 2000; 22(2):5-10. PubMed ID: 11883466
[No Abstract] [Full Text] [Related]
6. Going off-label without venturing off-course: evidence and ethical off-label prescribing.
Largent EA; Miller FG; Pearson SD
Arch Intern Med; 2009 Oct; 169(19):1745-7. PubMed ID: 19858430
[No Abstract] [Full Text] [Related]
7. Be wary of recommending off-label use of meds.
Luttrull S
Adv Nurse Pract; 2001 Feb; 9(2):18. PubMed ID: 12416047
[No Abstract] [Full Text] [Related]
8. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
9. Study population selection.
Treiman DM
Epilepsy Res Suppl; 1993; 10():125-35. PubMed ID: 8251088
[No Abstract] [Full Text] [Related]
10. FDA warns sellers of nicotine lollipops, lip balm.
FDA Consum; 2002; 36(4):5-6. PubMed ID: 12184310
[No Abstract] [Full Text] [Related]
11. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
[TBL] [Abstract][Full Text] [Related]
12. Interview with Gary L. Yingling, J.D.
Yingling GL
Qual Manag Health Care; 1999; 7(3):45-7. PubMed ID: 10537462
[No Abstract] [Full Text] [Related]
13. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
Zelenay JL
Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
[No Abstract] [Full Text] [Related]
14. Dying to live.
Nat Med; 2006 Jun; 12(6):593. PubMed ID: 16760985
[No Abstract] [Full Text] [Related]
15. Striking the right balance.
Nat Rev Drug Discov; 2006 Nov; 5(11):879. PubMed ID: 17117516
[No Abstract] [Full Text] [Related]
16. Institute of Medicine's new drug safety report: implications for Canada.
Cassels A
CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
[No Abstract] [Full Text] [Related]
17. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
Milton MN; Horvath CJ
Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
[No Abstract] [Full Text] [Related]
18. Who really assures prescription drug quality?
J Indiana State Med Assoc; 1979 Mar; 72(3):164. PubMed ID: 422862
[No Abstract] [Full Text] [Related]
19. Assessing potential risks and evaluating expected benefits.
Shaya FT; Gu A
Manag Care Interface; 2005 May; 18(5):27-30. PubMed ID: 15941187
[TBL] [Abstract][Full Text] [Related]
20. Billion-dollar market blossoms as botanicals take root.
Glaser V
Nat Biotechnol; 1999 Jan; 17(1):17-8. PubMed ID: 9920256
[No Abstract] [Full Text] [Related]
[Next] [New Search]
